Stephen Popkin, MD
Psychiatry · Denver, CONPI 1326004797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.7% of the total. Reporting peaked in 2019 at $1,350 and has fallen 67.1% since, to $445 in 2025. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$1K
- Lundbeck LLC$586
- Alkermes, Inc.$436
- Takeda Pharmaceuticals U.S.A., Inc.$433
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,97799%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $1,484 |
| Sunovion Pharmaceuticals Inc. | 47 | $1,047 |
| Lundbeck LLC | 30 | $586 |
| Alkermes, Inc. | 15 | $436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $433 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $371 |
| Otsuka America Pharmaceutical, Inc. | 16 | $329 |
| Teva Pharmaceuticals USA, Inc. | 7 | $177 |
| Idorsia Pharmaceuticals US Inc | 7 | $127 |
| Shire North American Group Inc | 6 | $118 |
| Merck | 6 | $108 |
| Vanda Pharmaceuticals Inc. | 4 | $98 |
| Axsome Therapeutics, Inc. | 3 | $94 |
| Adlon Therapeutics L.p. | 4 | $92 |
| Neurocrine Biosciences, Inc. | 4 | $89 |
| Bausch Health US, LLC | 4 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $56 |
| Almatica Pharma LLC | 2 | $47 |
| Eisai Inc. | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Corium, LLC | 2 | $31 |
| Tris Pharma Inc | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Neos Therapeutics, LP | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,016 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 36 | $30,127 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $14,590 |
| QuviviqDaridorexant Hcl | 25 | $12,097 |
| DayvigoLemborexant | 19 | $11,391 |
| Atomoxetine Hcl | 17 | $2,689 |
| Tranylcypromine Sulfate | 12 | $2,592 |
| Aripiprazole | 22 | $2,272 |
| Bupropion XlBupropion Hcl | 41 | $1,854 |
| Quetiapine Fumarate | 73 | $1,358 |
| Clozapine | 26 | $1,291 |
| Methylphenidate Hcl | 36 | $1,220 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $1,205 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,170 |
| Lurasidone Hcl | 25 | $1,139 |
| Clonazepam | 78 | $1,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $433 | $30,12736 claims |
| Axsome Therapeutics, Inc.Auvelity | $94 | $14,59012 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $127 | $12,09725 claims |
| Eisai Inc.Dayvigo | $47 | $11,39119 claims |
| Almatica Pharma LLCSertraline Hcl | $47 | $20317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Denver
- Jeffrey RichmondDenver$424K
- Brenda CzabanDenver$25K
- Robert ClarkDenver$14K
- Katy McLaughlinDenver$7K
- Sara MarkeyDenver$5K
- Joseph MendozzaDenver$3K
- John HardyPueblo$828K
- Larry SandersLittleton$760K
- Jennifer FrenchGlendale$115K
- Charles ParkLone Tree$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.